1
|
Nguyen TV, Ngwe Tun MM, Cao MT, Dao HM, Luong CQ, Huynh TKL, Nguyen TTT, Hoang TND, Morita K, Le TQM, Pham QD, Takamatsu Y, Hasebe F. Serological and Molecular Epidemiology of Chikungunya Virus Infection in Vietnam, 2017-2019. Viruses 2023; 15:2065. [PMID: 37896842 PMCID: PMC10611313 DOI: 10.3390/v15102065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 09/30/2023] [Accepted: 10/05/2023] [Indexed: 10/29/2023] Open
Abstract
Chikungunya fever is an acute febrile illness caused by the chikungunya virus (CHIKV), which is transmitted by Aedes mosquitoes. Since 1965, only a few studies with limited scope have been conducted on CHIKV in Vietnam. Thus, this study aimed to determine the seroprevalence and molecular epidemiology of CHIKV infection among febrile patients in Vietnam from 2017 to 2019. A total of 1063 serum samples from 31 provinces were collected and tested for anti-CHIKV IgM and IgG ELISA. The 50% focus reduction neutralization test (FRNT50) was used to confirm CHIKV-neutralizing antibodies. Quantitative real-time RT-PCR (RT-qPCR) was performed to confirm the presence of the CHIKV genome. The results showed that 15.9% (169/1063) of the patients had anti-CHIKV IgM antibodies, 20.1% (214/1063) had anti-CHIKV IgG antibodies, 10.4% (111/1063) had CHIKV-neutralizing antibodies, and 27.7% (130/469) of the samples were positive in RT-qPCR analysis. The E1 CHIKV genome sequences were detected among the positive RT-qPCR samples. Our identified sequences belonged to the East/Central/South/African (ECSA) genotype, which has been prevalent in Vietnam previously, suggesting CHIKV has been maintained and is endemic in Vietnam. This study demonstrates a high prevalence of CHIKV infection in Vietnam and calls for an annual surveillance program to understand its impact.
Collapse
Affiliation(s)
- Thanh Vu Nguyen
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; (T.V.N.); (K.M.)
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Mya Myat Ngwe Tun
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; (T.V.N.); (K.M.)
- DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki 852-8523, Japan
- Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, Izumo 690-8504, Japan
| | - Minh Thang Cao
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Huy Manh Dao
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Chan Quang Luong
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Thi Kim Loan Huynh
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Thi Thanh Thuong Nguyen
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Thi Nhu Dao Hoang
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Kouichi Morita
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; (T.V.N.); (K.M.)
- DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki 852-8523, Japan
| | - Thi Quynh Mai Le
- National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam;
| | - Quang Duy Pham
- Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam; (M.T.C.); (H.M.D.); (C.Q.L.); (T.K.L.H.); (T.T.T.N.); (T.N.D.H.); (Q.D.P.)
| | - Yuki Takamatsu
- Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan; (T.V.N.); (K.M.)
- DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki 852-8523, Japan
| | - Futoshi Hasebe
- Vietnam Research Station, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan
| |
Collapse
|
2
|
Taurel AF, Luong CQ, Nguyen TTT, Do KQ, Diep TH, Nguyen TV, Cao MT, Hoang TND, Huynh PT, Huynh TKL, Le MH, Nealon J, Moureau A. Age distribution of dengue cases in southern Vietnam from 2000 to 2015. PLoS Negl Trop Dis 2023; 17:e0011137. [PMID: 36827445 PMCID: PMC9994699 DOI: 10.1371/journal.pntd.0011137] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 03/08/2023] [Accepted: 02/02/2023] [Indexed: 02/26/2023] Open
Abstract
BACKGROUND Dengue is the most common vector-borne viral infection. In recent times, an increase in the age of cases with clinical dengue has been reported in the national surveillance system and published literature of Vietnam. This change not only alter the risk of transmission and disease burden in different populations but also will impact for prevention and control strategies. A retrospective study was conducted from 2000 to 2015 in 19 provinces of southern Vietnam to describe the changes in age distribution of dengue cases and circulating serotypes. METHODOLOGY/PRINCIPAL FINDINGS The study is a time trend analysis of the data aggregated from the database of dengue surveillance system. The database consisted of clinically diagnosed and laboratory-confirmed cases of dengue in southern Vietnam from 2000 to 2015. In the study period, the mean age of dengue cases increased from 12.2 ± 8.8 years old (y/o) to 16.8 ± 13.3 y/o between 2000 and 2015. Majority of severe cases were observed in the age group of 5-9 y/o and 10-14 y/o. Overall, the mortality and case fatality rates (CFR) were lowest during 2010 to 2015, and all four serotypes of dengue were observed. CONCLUSIONS/SIGNIFICANCE With the exception of severe form, the age distribution of clinical cases of dengue appears to be shifting towards older age groups. An increase in the mean age of clinical cases of dengue has been observed in southern Vietnam over the past decade, and the highest incidence was observed in age group of 5-14 y/o. All serotypes of dengue were in circulation.
Collapse
Affiliation(s)
| | | | | | - Kien Quoc Do
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Thanh Hai Diep
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Thanh Vu Nguyen
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Minh Thang Cao
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | | | | | | | - Minh Hieu Le
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | | | | |
Collapse
|
3
|
Tran NH, Chansinghakul D, Chong CY, Low CY, Shek LP, Luong CQ, Fargo C, Wartel TA, Sun S, Skipetrova A, Bouckenooghe A. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Hum Vaccin Immunother 2019; 15:2315-2327. [PMID: 30724660 PMCID: PMC6816352 DOI: 10.1080/21645515.2019.1578595] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV). Participants (2–45 years) received three doses of CYD-TDV or control at 0, 6, and 12 months. Dengue plaque reduction neutralization test (PRNT50) antibody titers were measured in both studies. Cytokine-producing antigen-specific CD4+ and CD8+ T-cells were quantified to assess cell-mediated immunity (CMI) in Singapore. Post-hoc analyses were carried out for participants aged <9 and ≥9 years old. Related and fatal serious adverse events (SAEs) were collected during long-term follow-up. Of participants who received ≥1 CYD-TDV injection in Singapore (n = 1198) and Vietnam (n = 180), 87% and 92% participants completed long-term follow-up, respectively. At four years, geometric mean titers (GMTs) in participants who received CYD-TDV ranged from 30.2 1/dil (95% CI 23.9–38.3) to 73.7 (49.3–110) 1/dil in Vietnam and 9.73 1/dil (95% CI 8.28–11.4) to 21.8 (18.9–25.1) 1/dil in Singapore. Interferon and interleukin-13 levels were lower at four years than one year post-vaccination but were still present. Tumor necrosis factor-α levels at four years were similar to those after the third vaccine dose. Seropositivity rates were higher at year four in participants who were seropositive vs. seronegative at baseline in both studies. No safety concerns were identified. CYD-TDV demonstrated long-term immunogenicity and was well-tolerated for four years after the third vaccine dose.
Collapse
Affiliation(s)
- Ngoc Huu Tran
- Department for Disease Control and Prevention, Pasteur Institute Ho Chi Minh City , Ho Chi Minh City , Vietnam
| | | | - Chia Yin Chong
- Infectious Diseases, Department of Pediatrics, KK Women's and Children's Hospital , Singapore
| | - Chian Yong Low
- Department of Infectious Disease, Singapore General Hospital , Singapore
| | - Lynette P Shek
- Department of Pediatrics, National University of Singapore , Singapore
| | - Chan Quang Luong
- Department for Disease Control and Prevention, Pasteur Institute Ho Chi Minh City , Ho Chi Minh City , Vietnam
| | - Carina Fargo
- Clinical Sciences and Medical Affairs Departments, Sanofi Pasteur , Singapore
| | - T Anh Wartel
- Clinical Sciences and Medical Affairs Departments, Sanofi Pasteur , Singapore
| | - Sunny Sun
- Biostatistic and Programming Department, Sanofi , Beijing , China
| | | | - Alain Bouckenooghe
- Clinical Sciences and Medical Affairs Departments, Sanofi Pasteur , Singapore
| |
Collapse
|
4
|
Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65. [PMID: 25018116 DOI: 10.1016/s0140-6736(14)61060-6] [Citation(s) in RCA: 704] [Impact Index Per Article: 70.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
BACKGROUND An estimated 100 million people have symptomatic dengue infection every year. This is the first report of a phase 3 vaccine efficacy trial of a candidate dengue vaccine. We aimed to assess the efficacy of the CYD dengue vaccine against symptomatic, virologically confirmed dengue in children. METHODS We did an observer-masked, randomised controlled, multicentre, phase 3 trial in five countries in the Asia-Pacific region. Between June 3, and Dec 1, 2011, healthy children aged 2-14 years were randomly assigned (2:1), by computer-generated permuted blocks of six with an interactive voice or web response system, to receive three injections of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV), or placebo, at months 0, 6, and 12. Randomisation was stratified by age and site. Participants were followed up until month 25. Trial staff responsible for the preparation and administration of injections were unmasked to group allocation, but were not included in the follow-up of the participants; allocation was concealed from the study sponsor, investigators, and parents and guardians. Our primary objective was to assess protective efficacy against symptomatic, virologically confirmed dengue, irrespective of disease severity or serotype, that took place more than 28 days after the third injection. The primary endpoint was for the lower bound of the 95% CI of vaccine efficacy to be greater than 25%. Analysis was by intention to treat and per procotol. This trial is registered with ClinicalTrials.gov, number NCT01373281. FINDINGS We randomly assigned 10,275 children to receive either vaccine (n=6851) or placebo (n=3424), of whom 6710 (98%) and 3350 (98%), respectively, were included in the primary analysis. 250 cases of virologically confirmed dengue took place more than 28 days after the third injection (117 [47%] in the vaccine group and 133 [53%] in the control group). The primary endpoint was achieved with 56·5% (95% CI 43·8-66·4) efficacy. We recorded 647 serious adverse events (402 [62%] in the vaccine group and 245 [38%] in the control group). 54 (1%) children in the vaccine group and 33 (1%) of those in the control group had serious adverse events that happened within 28 days of vaccination. Serious adverse events were consistent with medical disorders in this age group and were mainly infections and injuries. INTERPRETATION Our findings show that dengue vaccine is efficacious when given as three injections at months 0, 6, and 12 to children aged 2-14 years in endemic areas in Asia, and has a good safety profile. Vaccination could reduce the incidence of symptomatic infection and hospital admission and has the potential to provide an important public health benefit. FUNDING Sanofi Pasteur.
Collapse
Affiliation(s)
| | - Ngoc Huu Tran
- Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Sri Rezeki S Hadinegoro
- Department of Child Health, Medical School, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | | | | | - Mary Noreen Chua
- Chong Hua Hospital, Cebu City Guadalupe Health Center Annex, Guadalupe, Cebu City, Philippines
| | | | - Kusnandi Rusmil
- Child Health Department, Hasan Sadikin Hospital-Faculty of Medicine, Padjadjaran University, Bandung, Indonesia
| | - Dewa Nyoman Wirawan
- Department of Preventive Medicine, School of Medicine, Udayana University, Denpasar, Bali, Indonesia
| | | | - Punnee Pitisuttithum
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand
| | - Usa Thisyakorn
- Dengue Project Banpong-Photharam, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand
| | - In-Kyu Yoon
- Department of Virology, US Army Medical Component-Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), US Army Medical Component, Bangkok, Thailand
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lam SK, Burke D, Capeding MR, Chong CK, Coudeville L, Farrar J, Gubler D, Hadinegoro SR, Hanna J, Lang J, Lee HL, Leo YS, Luong CQ, Mahoney R, Mcbride J, Mendez-Galvan J, Ng LC, Nimmannitya S, Ooi EE, Shepard D, Smit J, Teyssou R, Thomas L, Torresi J, Vasconcelos P, Wirawan DN, Yoksan S. Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine 2011; 29:9417-22. [DOI: 10.1016/j.vaccine.2011.08.047] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Accepted: 08/09/2011] [Indexed: 11/29/2022]
|